SCHEMBL259704

SCHEMBL259704

Cc1cccc(NC(=O)c2ccccc2Cl)c1

nearest known ligand 0.82

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNK3 O14649 2/20 0.82
KCNK9 Q9NPC2 2/20 0.82
MEN1 O00255 5/20 0.70
KMT2A Q03164 5/20 0.70
ALDH1A1 P00352 3/20 0.70
L3MBTL1 Q9Y468 1/20 0.65
MAPT P10636 2/20 0.64
CRHBP P24387 1/20 0.64
CRHR2 Q13324 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
F2R P25116 1/20 0.64
RAB9A P51151 1/20 0.64
GAA P10253 1/20 0.60
HSD17B10 Q99714 1/20 0.60
KDM4E B2RXH2 1/20 0.60
POLB P06746 1/20 0.60
HPGD P15428 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15177176 0.90 KCNK3 (1.00) KCNK3KCNK9MEN1KMT2AMAPT
SCHEMBL28608407 0.87 RAB9A (0.68) KCNK3KCNK9MEN1KMT2AL3MBTL1
SCHEMBL882791 0.86 KCNK3 (0.75) KCNK3KCNK9MEN1KMT2AALDH1A1
SCHEMBL533767 0.84 KCNK3 (0.81) KCNK3KCNK9MEN1KMT2AALDH1A1
SCHEMBL15778718 0.84 FADS1 (0.74) KCNK3KCNK9MEN1KMT2AALDH1A1
SCHEMBL3356211 0.83 MEN1 (1.00) KCNK3KCNK9MEN1KMT2AALDH1A1
SCHEMBL259352 0.83 MEN1 (0.72) KCNK3KCNK9MEN1KMT2AALDH1A1
SCHEMBL31424193 0.83 MEN1 (0.72) KCNK3KCNK9MEN1KMT2AALDH1A1
SCHEMBL16941525 0.83 MEN1 (0.72) KCNK3KCNK9MEN1KMT2AALDH1A1
SCHEMBL19442228 0.82 SMN1; SMN2 (0.62) KCNK3KCNK9MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10442779-B2 Compositions and methods for treating Friedreich's ataxia FRATAGENE THERAPEUTICS S.R.L. (IT) 2019-10-15 US disclosed
WO-2016046759-A2 COMPOSITIONS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA FRATAGENE THERAPEUTICS LTD. (IT) 2016-03-31 WO disclosed
US-20160083358-A1 COMPOSITIONS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA FRATAGENE THERAPEUTICS S.R.L. (IT) 2016-03-24 US disclosed
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
EP-1277738-B1 CONDENSED HETEROARYL DERIVATIVES ASTELLAS PHARMA INC (JP) 2011-03-30 EP disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed
US-4123554-A Fungicidal and germicidal benzanilides KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) 1978-10-31 US disclosed
US-4069335-A BENZANILIDES, FUNGICIDES KUMIAL CHEMICAL INDUSTRY CO., LTD. (JA) 1978-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A KCNK3 1197/4885KCNK9 1798/4885MEN1 3330/4885
US-20070037805-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A KCNK3 1197/4885KCNK9 1798/4885MEN1 3330/4885
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A KCNK3 1197/4885KCNK9 1798/4885MEN1 3330/4885
US-20160083358-A1 COMPOSITIONS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA ATXN10, ATXN2, ATXN2L KCNK3 2486/4885KCNK9 3144/4885MEN1 3654/4885
US-10442779-B2 Compositions and methods for treating Friedreich's ataxia ATXN10, ATXN2, ATXN2L KCNK3 2486/4885KCNK9 3144/4885MEN1 3654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.